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ABSTRACT 
The present study depicts the enhancement of antitumor efficacy and the safety usage of the DOX with the combination of the co-
enzymes. The drugs were prepared by the diffusion evaporation method of the solvent and were also easily optimized. The 
therapeutic antitumor efficacy is found to be signification with the combinations undertaken for the study. The improvements of the 
processes were indicated in the form of the literature review, which was analyzed for the purpose of proving the therapeutic efficacy 
in the drugs. The nanocarriers’ multifunctional characteristics and the importance of the liposome in the treatment of the tumor were 
focused in this study, which enables the enhancement of the antitumor efficacy.  
Keywords: Nanomedicine, drug delivery, Doxorubicin, anti-cancer. 
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INTRODUCTION 
In the field of cancer treatment, large changes can be 
found. There are several doctors and medical scientists 
conducting research to know the effective treatment of 
cancer.
1,2
 Moreover, in this matter, development of 
doxorubicin drug is significant. Doxorubicin is an 
important drug, which is used in chemotherapy to treat 
various types of cancer.
3
 Some of the common forms of 
cancer, where doxorubicin can be employed efficiently, 
are bladder cancer, breast cancer, Kaposi’s sarcoma, 
lymphoma as well as acute lymphocytic leukemia.
4,5
 
This important drug is mostly sold under the trade names 
Adriamycin. In the cancer treatment, usages of nano-
medicines also play important roles. 
6
The nano-medicine 
is considered as the medical application of the 
nanotechnology.
7,8
 The usage of nanomaterials along 
with organic devices is an effective treatment for tumor 
and is widely used in cancer treatment as by this process 
efficiently kills the tumor cells.
9
 Besides this, it is 
broadly observed that for the Chemotherapy two or 
multiple drugs are used simultaneously. 
10,11
The cause of 
multidrug dose is the limitation of a single drug in the 
treatment of cancer.
12-14
 The usage of a single 
chemotherapeutic drug is not as much effective as a 
combination of multi-drug in the anti-tumor treatment.
15
 
In addition, the only drugs have some limitations like the 
development of the resistance of the drug, limited 
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administration of clinical uses and high toxicity, multi-
drug use to be administrated. 
16
 
Doxorubicin with Pyrrolidine Dithiocarbamate 
For the treatment of cancer, doxorubicin is used with a 
combination of several other drugs. Moreover, in this 
case, its conjunction with Pyrrolidine dithiocarbamate 
(PDTC) is very useful.
17
 Co-administration of 
Pyrrolidine dithiocarbamate (PDTC) and Doxorubicin 
via micellar nanoparticles used to be performed to attain 
actively targeted delivery of the drugs. Apart from this, 
this combination supports in overcoming multi-drug 
resistance.
18
 The self-assembled micellar nanoparticles 
from copolymer folate-chitosan were deployed since the 
carrier to co-administration of pyrrolidine 
dithiocarbamate (PDTC) and doxorubicin to attain the 
aimed doxorubicin release along with pH reactive drug 
discharge. Besides this, the process of administrating 
these drugs combination support in overcoming 
doxorubicin multidrug resistance. The efficient 
amalgamation of FA-CS used to be decided by the 
NMR. The standard size of particles was not adequate to 
attain longevity throughout the systematic circulation. 
The lesser CACs in neutral as well as alkalescent 
situations than an acid pH probably led to keep the good 
constancy of micellar nanoparticles in the blood stream. 
The doxorubicin along with PDTC encapsulating the 
efficacy of the micellar nanoparticles were 77.64 and 
86.54 wt%, whereas the loading substance was 12.34 
and 15.32% correspondingly. The drug doxorubicin at 
neutral or alkalescent pH release was slow and constant, 
but in weak acidic condition, the release was much 
quicker near to 75-95% of its whole drug substance.  
Doxorubicin with Paclitaxel  
The limitations regarding the antitumor are indicated by 
the single use of the chemotherapeutic drugs.
19,20
 For the 
purpose of removing the toxicity amount of the drugs, 
the mixture of the Paclitaxel and the Doxorubicin is 
being used for decreasing the toxicity of the drugs used 
for the treatment of the tumors. Therefore, the mixture of 
two or more therapeutic drugs was proposed with 
indicating the decrement of each drug. The delivery of 
the chemotherapeutic drug is being provided by the aid 
of the drug carriers which are the micelles, inorganic 
nanoparticles, and the liposomes. The core shell of the 
nanoparticles is doubly emulsified from an amphiphilic 
copolymer Methoxy poly (ethylene glycol)-poly 
(lactide-co-glycolide) or the mPEG-PLGA.
21
 This aids 
in creating an advantage for initiation of the fabrication 
process that can be improved by the process of the 
double emulsion. The nanoparticles are seemed to be not 
able to deliver the hydrophilic doxorubicin and the 
hydrophilic paclitaxel. Therefore, the loading of the 
drugs is undertaken for the purpose of possessing a 
better polydispersity, and it also indicates controlled 
nature of the size distribution. The co-delivery of the 
nanocarriers are suppressed the tumor cells in a more 
efficient way than the DOX and the TAX with keeping 
the same concentrations.  
Doxorubicin with siRNA  
The glioma is considered as a fatal malignancy in the 
brain which cannot be successfully treated with aid of 
chemotherapy.
22,23
 Thus, the development of various 
techniques is undertaken for the purpose of providing 
appropriate treatment for the glioma with considering 
the clinical importance. On the basis of this factor, the 
folate functioned multifunctional nanocarrier is created 
in the lab which is effective for the co-delivering the 
DOX and the siRNA into the rat C6 glioma cells.
24
 
Therefore, the achievement of this experiment created a 
great success with expressing the folate receptor cells. 
With the aid of this, the anti-apoptotic responses in the 
C6 cells were activated and were also revealed by the 
molecular biological investigations.
25
 The study 
undertaken in the case of the animals provided an 
appropriate example for the purpose of indicating a 
distinct down-regulation of the anti-apoptotic BCL-2 
gene. It also showed the outstanding up-regulation of 
Bax gene which resulted in activation of the caspase-3. 
The up-regulation is also remarkably seen in the cell 
apoptosis in the tumor tissues. Henceforth, the healing 
effect can be appropriately achieved with using folate-
targeted co-delivery plan.  
Doxorubicin along with BCL-2 SIRNA  
Co-delivery or combined administration of DOX along 
with siRNAs by mesoporous silica nanoparticles were 
provided into the multidrug-resistance cancer cells for 
the purpose of achieving the minimum premature 
discharge. It substantially improves the efficiency of 
chemotherapy with overcoming the nonpump resistance 
as well as avoiding the efflux pump resistance.
26
 In this 
matter, it must be remembered that growth of resistance 
regarding the multidrug in cancer cells generates the 
adverse effects that are shown to be the important 
obstacles for successful chemotherapy. The therapists 
are trying to develop effective strategies to overcome the 
drug resistance and to target the particular tumor with a 
minimum discharge of the premature drug. This 
particular strategy has an immense impact in the curing 
process of cancer. The multidrug resistance is a 
resistance phenotype where the cancer cells turn into 
resistance simultaneously to multiply the drugs. The 
apparent structural similarity is not identified as well as 
the diverse molecular targets are seen. The multidrug 
resistance or MDR can be segregated into two different 
classes: pump resistance and non-pump resistance. The 
causes of pump resistance are few proteins, which make 
membrane bound adenosine triphosphate (ATP). The 
key mechanism of non-pump resistance is indicated in 
the form of activating cellular anti-apoptotic defense 
initially by Bcl-2 protein.
27
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Schematic diagram of co-administration system depends on MSNs for delivering doxorubicin and Bcl-2- target siRNA 
Doxorubicin with Verapamil  
For efficient administration of cancer chemotherapy, the 
greatest obstacle is multidrug resistance (MDR). 
28-30
 
The multidrug resistance (MDR) is frequently linked 
with up-regulation of the permeability-glycoprotein 
(Pgp), which is an ATP-dependent efflux pump and 
support in decreasing intracellular drug concentration. 
For overcoming the multidrug resistance (MDR), a 
range of approaches has been explored, including the 
usage of cytotoxic drugs combined with Pgp inhibitor. 
Verapamil (VER) is a calcium channel adversary has 
been exhibit Pgp inhibitory activity. However, the 
amount of dose of VER needed for Pgp blockade (2-
6µM) is substantially higher in comparison to the 
present clinical treatment for arrhythmia and possibly 
induce cardiotoxicity. In this matter, it is observed that 
liposomal delivery of VER can decrease its 
cardiotoxicity by declining free VER concentration in 
the systemic circulation.
31
 It is observed that liposomes 
along with doxorubicin and verapamil (VER) and mixed 
with transferring (Tf-L-DOX/VER) were produced as 
well as examined in K562 Leukemia Cells. The 
formulation is to target the tumor cells, decreasing 
cardiotoxicity of Doxorubicin and Verapamil. Besides 
this, this combination support in overcoming P-
glycoprotein (Pgp) mediated multidrug resistance 
phenotype. The mixer of TfR targeting, co-
encapsulation of doxorubicin and verapamil is shown to 
be highly efficient for overcoming the drug resistance in 
the K562 leukemia cell.              
SUMMARY  
The combined administration of drugs in cancer therapy 
is most effective. Moreover, for the treatment of a 
tumor, the drug combinations are used effectively.
32
 
Mostly doxorubicin drug is utilized in the treatment of 
cancer or tumor along with other drugs. Along with 
doxorubicin, several drugs like  Pyrrolidine 
dithiocarbamate (PDTC), Paclitaxel, Sirna by 
multifunctional nanocarrier, Bcl-2 Sirna by Mesoporous 
Silica Nanoparticles, and Verapamil via transferrin 
liposome very useful in the treatment of cancer, 
specifically for tumor treatment. It supports in reducing 
the multidrug resistance.   
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